MX2020007312A - Regimenes de dosificacion superior de g1t38. - Google Patents
Regimenes de dosificacion superior de g1t38.Info
- Publication number
- MX2020007312A MX2020007312A MX2020007312A MX2020007312A MX2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A MX 2020007312 A MX2020007312 A MX 2020007312A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage regimes
- superior
- ratio
- superior dosage
- mean auc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
Un régimen de dosificación oral humana de G1T38 que ofrece una relación (media del AUC(0-24),ss(h*ng/mL))/(dosis (mg)) menor que 5 y/o una relación (media del AUC(0-24),ss (h*ng/mL))/(recuento absoluto de neutrófilos (células/mm3)) =1,25 en el día 22 de una dosificación.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862614952P | 2018-01-08 | 2018-01-08 | |
US201862679575P | 2018-06-01 | 2018-06-01 | |
US201962788017P | 2019-01-03 | 2019-01-03 | |
PCT/US2019/012720 WO2019136451A1 (en) | 2018-01-08 | 2019-01-08 | G1t38 superior dosage regimes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007312A true MX2020007312A (es) | 2021-01-08 |
Family
ID=67143921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007312A MX2020007312A (es) | 2018-01-08 | 2019-01-08 | Regimenes de dosificacion superior de g1t38. |
Country Status (16)
Country | Link |
---|---|
US (2) | US11357779B2 (es) |
EP (1) | EP3738084A4 (es) |
JP (1) | JP2021509680A (es) |
KR (1) | KR20200108867A (es) |
CN (1) | CN111837146A (es) |
AU (1) | AU2019205821A1 (es) |
BR (1) | BR112020013915A2 (es) |
CA (1) | CA3087570A1 (es) |
CO (1) | CO2020008825A2 (es) |
IL (1) | IL275708A (es) |
MX (1) | MX2020007312A (es) |
PE (1) | PE20210121A1 (es) |
PH (1) | PH12020551050A1 (es) |
RU (1) | RU2020123665A (es) |
SG (1) | SG11202005937QA (es) |
WO (1) | WO2019136451A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105407889B (zh) * | 2013-03-15 | 2018-06-01 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
CN110177554B (zh) | 2017-01-06 | 2023-06-02 | G1治疗公司 | 用于治疗癌症的组合疗法 |
WO2019199883A1 (en) * | 2018-04-09 | 2019-10-17 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
EP4153597A1 (en) | 2020-05-19 | 2023-03-29 | G1 Therapeutics, Inc. | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
CA3188821A1 (en) * | 2020-08-13 | 2022-02-17 | Lars ANDERS | Combination therapy |
KR20230157379A (ko) * | 2021-03-17 | 2023-11-16 | 암젠 인크 | 소토라십 투약 요법 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0509580A (pt) | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
WO2006061712A2 (en) * | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
EA200900799A1 (ru) | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
EA201001030A1 (ru) | 2007-12-19 | 2011-02-28 | Амген Инк. | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла |
ES2622559T3 (es) | 2008-07-29 | 2017-07-06 | Nerviano Medical Sciences S.R.L. | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico |
WO2010020675A1 (en) | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
JP2012504646A (ja) | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 選択的サイクリン依存性キナーゼ4/6阻害剤を用いた化学療法化合物に対する造血系の防護 |
JP2012504645A (ja) | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物 |
JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
JP2012526850A (ja) | 2009-05-13 | 2012-11-01 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | サイクリン依存性キナーゼ阻害剤及びその用法 |
JP5826772B2 (ja) * | 2010-02-16 | 2015-12-02 | ノヴォ ノルディスク アー/エス | コンジュゲートタンパク質 |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
SI2632467T1 (sl) | 2010-10-25 | 2016-10-28 | G1 Therapeutics, Inc. | Inhibitorji CDK |
WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
DK2688887T3 (en) | 2011-03-23 | 2015-06-29 | Amgen Inc | DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3 |
ES2676180T3 (es) | 2011-07-01 | 2018-07-17 | Novartis Ag | Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer |
CA2881993C (en) | 2011-07-27 | 2017-05-09 | Astrazeneca Ab | Substituted 4-methoxy-n3-(pyrimidin-2-yl)benzene-1,3-diamine compounds, and salts thereof |
EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
WO2014022830A2 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
CN105407889B (zh) | 2013-03-15 | 2018-06-01 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
JP6435315B2 (ja) * | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
CN106029099A (zh) | 2013-08-28 | 2016-10-12 | 诺华股份有限公司 | 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合 |
US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
WO2015084892A1 (en) | 2013-12-02 | 2015-06-11 | Cornell University | Methods for treating b cell proliferative disorders |
WO2015101293A1 (zh) | 2013-12-31 | 2015-07-09 | 山东轩竹医药科技有限公司 | 激酶抑制剂及其用途 |
WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Btk抑制劑、pi3k抑制劑、jak-2抑制劑、及/或cdk4/6抑制劑的治療組合物 |
US20170231995A1 (en) * | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
ES2761885T3 (es) | 2015-08-28 | 2020-05-21 | Novartis Ag | Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer |
WO2017160568A1 (en) | 2016-03-16 | 2017-09-21 | Eli Lilly And Company | Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer |
WO2017193141A1 (en) | 2016-05-06 | 2017-11-09 | Siyuan Zhang | Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer |
WO2017223115A1 (en) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
US20190175598A1 (en) | 2016-08-23 | 2019-06-13 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
EP3541389A1 (en) | 2016-11-16 | 2019-09-25 | Pfizer Inc | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
CN110035759A (zh) | 2016-12-05 | 2019-07-19 | G1治疗公司 | 化疗方案期间免疫反应的保持 |
CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
US11083722B2 (en) | 2017-03-16 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
WO2018183479A1 (en) | 2017-03-30 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors |
WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
CA3067023A1 (en) | 2017-06-12 | 2018-12-20 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
GB201709417D0 (en) | 2017-06-14 | 2017-07-26 | Inst Of Cancer Research: Royal Cancer Hospital | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer |
WO2018233620A1 (zh) | 2017-06-21 | 2018-12-27 | 江苏恒瑞医药股份有限公司 | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 |
CA3066778A1 (en) | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN110913861B (zh) * | 2017-06-29 | 2024-01-09 | G1治疗公司 | G1t38的形态学形式及其制造方法 |
US20200155566A1 (en) | 2017-08-03 | 2020-05-21 | Novartis Ag | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
WO2019108589A1 (en) | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
-
2019
- 2019-01-08 BR BR112020013915-7A patent/BR112020013915A2/pt unknown
- 2019-01-08 CN CN201980017478.6A patent/CN111837146A/zh active Pending
- 2019-01-08 WO PCT/US2019/012720 patent/WO2019136451A1/en unknown
- 2019-01-08 JP JP2020537622A patent/JP2021509680A/ja active Pending
- 2019-01-08 PE PE2020000908A patent/PE20210121A1/es unknown
- 2019-01-08 CA CA3087570A patent/CA3087570A1/en active Pending
- 2019-01-08 AU AU2019205821A patent/AU2019205821A1/en active Pending
- 2019-01-08 MX MX2020007312A patent/MX2020007312A/es unknown
- 2019-01-08 RU RU2020123665A patent/RU2020123665A/ru unknown
- 2019-01-08 SG SG11202005937QA patent/SG11202005937QA/en unknown
- 2019-01-08 KR KR1020207022923A patent/KR20200108867A/ko unknown
- 2019-01-08 EP EP19736263.5A patent/EP3738084A4/en active Pending
-
2020
- 2020-06-28 IL IL275708A patent/IL275708A/en unknown
- 2020-07-08 PH PH12020551050A patent/PH12020551050A1/en unknown
- 2020-07-08 US US16/924,033 patent/US11357779B2/en active Active
- 2020-07-16 CO CONC2020/0008825A patent/CO2020008825A2/es unknown
-
2022
- 2022-06-13 US US17/839,215 patent/US20230149406A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2020008825A2 (es) | 2020-07-31 |
PE20210121A1 (es) | 2021-01-19 |
AU2019205821A1 (en) | 2020-07-09 |
US20200405721A1 (en) | 2020-12-31 |
WO2019136451A1 (en) | 2019-07-11 |
CA3087570A1 (en) | 2019-07-11 |
IL275708A (en) | 2020-08-31 |
EP3738084A4 (en) | 2021-11-17 |
SG11202005937QA (en) | 2020-07-29 |
JP2021509680A (ja) | 2021-04-01 |
EP3738084A1 (en) | 2020-11-18 |
KR20200108867A (ko) | 2020-09-21 |
US11357779B2 (en) | 2022-06-14 |
PH12020551050A1 (en) | 2021-08-23 |
CN111837146A (zh) | 2020-10-27 |
BR112020013915A2 (pt) | 2020-12-01 |
RU2020123665A (ru) | 2022-02-10 |
US20230149406A1 (en) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551050A1 (en) | G1t38 superior dosage regimes | |
MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
MX2022006001A (es) | Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos. | |
MX2023001705A (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia. | |
EA201792595A1 (ru) | Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела | |
MX2021005992A (es) | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. | |
WO2019046568A8 (en) | High concentration dosage forms of pridopidine | |
JOP20220160A1 (ar) | مركبات فعّالة نحو مستقبلات نووية | |
ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
MX354080B (es) | Tratamiento de la esclerosis multiple (em) con campath 1h. | |
MX2021010338A (es) | Composicion farmaceutica que contiene acetominofeno e ibuprofeno. | |
MX2021001761A (es) | Formulaciones de ag10. | |
MX2022011711A (es) | Compuesto de oxofenilarsina deuterada y uso del mismo. | |
AU2021322255A8 (en) | Use of dexpramipexole for the treatment of moderate to severe asthma | |
EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
EA202091507A1 (ru) | Преимущественные режимы дозирования g1t38 | |
AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
WO2022081310A3 (en) | Inhaled pde-v inhibitor drugs | |
UA117784U (uk) | Спосіб профілактики рецидивування гіперпластичних процесів у жінок в пременопаузі | |
UA105588U (uk) | Спосіб лікування вегето-судинної дисфункції з гіпертензією у дітей | |
EA201692107A1 (ru) | Схема лечения тиакумициновым соединением | |
MX2022002038A (es) | Composicion farmaceutica para el tratamiento del insomnio. | |
MX2022012259A (es) | Compuestos activos frente a receptores nucleares. | |
Jing et al. | Grade Ⅳ myelosuppression after induction chemotherapy of TPF on oral cancer: clinical analysis of 29 cases | |
Mukhopadhyay et al. | Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients |